Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Leukemia, Myeloid, Acute 4Carcinoma, Non-Small-Cell Lung 3Myelodysplastic Syndromes 2Metastatic Solid Tumors 2Melanoma 2Solid Tumors 1Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer 1Recurrence 1Prostate Cancer Patients Undergoing Radical Prostatectomy 1Neoplasms 1Neoadjuvant Treatment for Locally Advanced Cervical Cancer 1Myeloproliferative Disorders 1Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Glioma 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1Cancer Pain 1Breast Neoplasms 1Breakthrough Pain 1Biliary Tract Neoplasms 1Advanced Malignant Neoplasm 1

Interventions

pembrolizumab 180Gemcitabine 168Paclitaxel 150Carboplatin 134Bevacizumab 126Cisplatin 113Docetaxel 112Cyclophosphamide 109Exercise 97Nivolumab 92Fluorouracil 88Capecitabine 85Dexamethasone 81Irinotecan 74Radiotherapy 68Oxaliplatin 68Pemetrexed 66Standard of Care 64Leucovorin 63Cetuximab 59Sorafenib 53Erlotinib Hydrochloride 53Drug Therapy 53Blood Specimen Collection 52Doxorubicin 50trametinib 47atezolizumab 47Ipilimumab 47Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasms × Infusions, Intravenous × Clear all
NCT01023958 2017-11-22

Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer

Boehringer Ingelheim

Phase 2 Completed
50 enrolled 29 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡